产品名称

FG-2216 - YM 311

产品货号

Axon 2570 CAS [223387-75-5] MF C12H9ClN2O4MW 280.66 Purity: 99% Soluble in 0.1N HCl(aq) and DMSO Description Orally active HIF prolyl 4-hydroxylase inhibitor (P4-HI; IC50 value 3.9 μM for PHD2) that increases plasma EPO levels up to 30-fold in hemodialysis (HD) patients, and reduces cardiac remodeling after myocardial infarction in rats independent of a reduction of collagen maturation or altering growth factors. KEYWORDS: FG-2216 | supplier | PHD inhibitor | YM 311 | FG2216 | YM311 | CAS [223387-75-5] | Hypoxia-signaling cascade | PHD-2 (HIF1) | PHD-4 (HIF1) | Inhibitor | hypoxia inducible factor | prolyl hydroxylase | EPO | hemodialysis | cardiac remodeling | myocardial infarction | collagen

产品价格

现货询价，电话：010-67529703

产品规格

产品品牌

axonmedchem

产品概述

产品详情

FG-2216 - YM 311

Based on 303 reference(s) in Google Scholar 10 10 303

Axon 2570

CAS [223387-75-5]

MF C12H9ClN2O4
MW 280.66

Purity: 99%
Soluble in 0.1N HCl(aq) and DMSO

FG-2216

Description

Orally active HIF prolyl 4-hydroxylase inhibitor (P4-HI; IC50 value 3.9 μM for PHD2) that increases plasma EPO levels up to 30-fold in hemodialysis (HD) patients, and reduces cardiac remodeling after myocardial infarction in rats independent of a reduction of collagen maturation or altering growth factors.

KEYWORDS: FG-2216 | supplier | PHD inhibitor | YM 311 | FG2216 | YM311 | CAS [223387-75-5] | Hypoxia-signaling cascade | PHD-2 (HIF1) | PHD-4 (HIF1) | Inhibitor | hypoxia inducible factor | prolyl hydroxylase | EPO | hemodialysis | cardiac remodeling | myocardial infarction | collagen

WM Bernhardt et al. Inhibition of prolyl hydroxylases increases erythropoietin production in ESRD. J Am Soc Nephrol. 2010 Dec;21(12):2151-6.

S Philipp et al. Stabilization of hypoxia inducible factor rather than modulation of collagen metabolism improves cardiac function after acute myocardial infarction in rats. Eur J Heart Fail. 2006 Jun;8(4):347-54.

YR Hong et al. [(4-Hydroxyl-benzo[4,5]thieno[3,2-c]pyridine-3-carbonyl)-amino]-acetic acid derivatives; HIF prolyl 4-hydroxylase inhibitors as oral erythropoietin secretagogues. Bioorg Med Chem Lett. 2013 Nov 1;23(21):5953-7.

MM Hsieh et al. HIF prolyl hydroxylase inhibition results in endogenous erythropoietin induction, erythrocytosis, and modest fetal hemoglobin expression in rhesus macaques. Blood. 2007 Sep 15;110(6):2140-7.

Angiogenesis Apoptosis Cell Signaling & Oncology Epigenetics PHD (HIF) Transcription Factors EC 1.14.11.2

Orally active HIF-PHD inhibitor that increases plasma EPO levels in vivo

Chemical name

2-(1-chloro-4-hydroxyisoquinoline-3-carboxamido)acetic acid

Parent CAS No.

[223387-75-5]

产品资料